Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
$1.515M
TTM
Current Assets
$162.5K
Q3 2023
Current Liabilities
$16.18M
Q3 2023
Current Ratio
1.0%
Q3 2023
Total Assets
$12.68M
Q3 2023
Total Liabilities
$16.18M
Q3 2023
Book Value
-$3.497M
Q3 2023
Cash
P/E
1.405
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Revenue YoY Change

No data

Revenues

Concept 2022 2021
Revenue $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2022 2021
Revenue $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

No data

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

No data

Operational Expenses

Concept 2022 2021
Selling, General & Admin $1.294M $334.3K
YoY Change 287.08%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.294M $334.3K
YoY Change 287.08%
Operating Profit
YoY Change

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021
Interest Expense $9.308M $9.674M
YoY Change -3.78%
% of Operating Profit
Other Income/Expense, Net -$1.110M
YoY Change

Income/Loss

Pretax Income

Income Tax

No data

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

No data

Net Income To Revenue Ratio

No data

Pretax & Net Income

Concept 2022 2021
Pretax Income $8.014M $8.230M
YoY Change -2.63%
Income Tax
% Of Pretax Income
Net Earnings $8.014M $8.230M
YoY Change -2.63%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.25 $0.25

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

No data

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

No data

Total Short-Term Assets

Property, Plant And Equipment

No data

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

No data

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

No data

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2022 2021
Cash & Short-Term Investments $128.7K $648.3K
YoY Change -80.15%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $248.2K $324.9K
YoY Change -23.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.206M $973.2K
YoY Change 23.89%
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $257.7M $255.0M
YoY Change 1.07%
Other Assets $0.00 $248.7K
YoY Change -100.0%
Total Long-Term Assets $257.7M $255.3M
YoY Change 0.97%
Total Assets $258.9M $256.2M
YoY Change
Accounts Payable $417.7K $68.70K
YoY Change 508.02%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.27M $68.70K
YoY Change 20673.23%
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $19.51M
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $19.51M
YoY Change -100.0%
Total Liabilities $14.27M $19.58M
YoY Change -27.11%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

No data

Free Cash Flow YoY

No data

Free Cash Flow Margin

No data

Dividends

Dividends

No data

Stock Price

Market Cap: $2.1296 Million

About PSYENCE BIOMEDICAL LTD.

Psyence Biomedical Ltd. is a life science biotechnology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Industry: Pharmaceutical Preparations Peers: Aptose Biosciences Inc. Xenon Pharmaceuticals Inc.